Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies

In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone...

Full description

Saved in:
Bibliographic Details
Published in:Osteoporosis international 2003-12, Vol.14 (12), p.1013-1019
Main Authors: TAUCHMANOVA, L, SELLERI, C, ESPOSITO, M, DI SOMMA, C, ORIO, F. JR, BIFULCO, G, PALOMBA, S, LOMBARDI, G, ROTOLI, B, COLAO, A
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Biological and medical sciences
Bisphosphonates
Body mass index
Bone density
Bone Density - drug effects
Bone Density Conservation Agents - administration & dosage
Bone Density Conservation Agents - adverse effects
Bones, joints and connective tissue. Antiinflammatory agents
Calcium - administration & dosage
Creatinine
Drug Administration Schedule
Etidronic Acid - administration & dosage
Etidronic Acid - adverse effects
Etidronic Acid - analogs & derivatives
Female
Femur Neck - drug effects
Femur Neck - physiopathology
Gynecology
Hematologic Neoplasms - surgery
Hematology
Hormone replacement therapy
Humans
Lumbar Vertebrae - drug effects
Lumbar Vertebrae - physiopathology
Male
Medical sciences
Metabolism
Obstetrics
Osteocalcin - blood
Osteoporosis
Osteoporosis - drug therapy
Osteoporosis - metabolism
Pharmacology. Drug treatments
Prospective Studies
Risedronate Sodium
Stem cell transplantation
Stem Cell Transplantation - methods
Time Factors
Treatment Outcome
Vitamin D - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone mineral density (BMD)
ISSN:0937-941X
1433-2965
DOI:10.1007/s00198-003-1520-2